Lin BioScience’s Subsidiary Belite Secures Additional US$15 Million Investment from Major International Fund

Belite, a subsidiary of Lin BioScience, announced that it has received an additional US$15 million investment (approximately NT$450 million) from the same major international fund. The financing was executed through the issuance of one American Depositary Share (ADS) and one unit of warrants per package, at US$65 per ADS (approximately NT$1,933 per share). Each warrant allows the purchase of one ADS at the same exercise price of US$65. The proceeds will be used to strengthen working capital and for general corporate purposes.